Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

作者：Chloe Orkin, Edwin DeJesus, Paul E. Sax, José Ramón Arribas, Samir K. Gupta, Claudia Martorell, Jeffrey L. Stephens, Hans‐Jürgen Stellbrink, David A. Wohl, Franco Maggiolo, Melanie Thompson, Daniel Podzamczer, Debbie Hagins, Jason Flamm, Cynthia Brinson, Amanda Clarke, Hailin Huang, Rima Acosta, Diana M. Brainard, Sean E Collins, Hal Martin · 发表于：The Lancet HIV · 年份：2020 · DOI：10.1016/s2352-3018(20)30099-0 · 被引用次数：140 · 研究领域：HIV/AIDS drug development and treatment、Hepatitis B Virus Studies、HIV Research and Treatment